Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PRINZIDE is a fixed-dose combination tablet containing hydrochlorothiazide (a thiazide diuretic) and lisinopril (an ACE inhibitor), approved in 1989. It is indicated for hypertension management in patients requiring dual antihypertensive therapy. The combination works synergistically to reduce blood pressure through natriuresis and vasodilation.
Product is in late-stage lifecycle with moderate competitive pressure; teams are typically focused on retention and cost management rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Careers on PRINZIDE teams center on managing a mature product through LOE transition, including defending market share against generics, optimizing pricing strategies, and ensuring market access. This role suits professionals experienced in lifecycle management and generic defense rather than new product launches.
Worked on PRINZIDE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.